RESUMEN
BACKGROUND: This is a case report of an asymptomatic SARS-CoV-2 infection associated with new-onset nephrotic syndrome in a pediatric patient. This is the third case of new-onset nephrotic syndrome in children associated with SARS-CoV-2 infection, but is the first case report describing a new-onset nephrotic syndrome presentation in a patient who had asymptomatic COVID-19 infection. CASE PRESENTATION: This is a case of a previously healthy 5 year old female who presented with new-onset nephrotic syndrome in the setting of an asymptomatic COVID-19 infection. She presented with progressive edema, and laboratory findings were significant for proteinuria and hypercholesterolemia. She was treated with albumin, diuretics, and corticosteroid therapy, and achieved clinical remission of her nephrotic syndrome within 3 weeks of treatment. Though she was at risk of hypercoagulability due to her COVID-19 infection and nephrotic syndrome, she was not treated with anticoagulation, and did not develop any thrombotic events. CONCLUSIONS: Our case report indicates that SARS-CoV-2 infection could be a trigger for nephrotic syndrome, even in the absence of overt COVID-19 symptoms.
Asunto(s)
Infecciones Asintomáticas , COVID-19 , Síndrome Nefrótico , Manejo de Atención al Paciente/métodos , Inducción de Remisión/métodos , COVID-19/complicaciones , COVID-19/diagnóstico , COVID-19/fisiopatología , Preescolar , Edema/diagnóstico , Edema/etiología , Femenino , Humanos , Hipercolesterolemia/diagnóstico , Hipercolesterolemia/etiología , Síndrome Nefrótico/sangre , Síndrome Nefrótico/etiología , Síndrome Nefrótico/terapia , Síndrome Nefrótico/orina , Proteinuria/diagnóstico , Proteinuria/etiología , SARS-CoV-2/aislamiento & purificación , Resultado del TratamientoRESUMEN
Management of ANCA-associated vasculitis (AAV) during the COVID-19 pandemic poses unique therapeutic challenges. An online survey was conducted to understand physician's choices for treating AAV during the COVID-19 pandemic. Web-based survey featuring nineteen questions was circulated amongst physicians across various specialties. The responses regarding immunosuppressive therapy for remission induction and maintenance, COVID-19 testing, and preventive measures were recorded. A total of 304 responses were recorded. Most of the respondents were from India (83.9%) and comprised rheumatologists (66%) in practice for ≥ 5 years (71%). Though a majority preferred Rituximab or intravenous cyclophosphamide (CYC) as a remission induction agent, a significant proportion opted for oral CYC and mycophenolate mofetil (MMF) also. Only one-third wanted to test for COVID-19 before initiating immunosuppressive therapy in patients with organ/life-threatening manifestations. Rituximab was the most favored maintenance therapy (47%), followed by azathioprine, MMF, and methotrexate. The results of this focused survey of managing AAV patients depict the real-world dilemmas and physicians' choices in this setting.
Asunto(s)
Vasculitis Asociada a Anticuerpos Citoplasmáticos Antineutrófilos/tratamiento farmacológico , Terapia de Inmunosupresión/métodos , Pautas de la Práctica en Medicina , Reumatología/métodos , Adulto , COVID-19/epidemiología , Prueba de COVID-19 , Femenino , Humanos , Inmunosupresores/uso terapéutico , Masculino , Persona de Mediana Edad , Pandemias , Inducción de Remisión/métodos , SARS-CoV-2 , Encuestas y CuestionariosAsunto(s)
Endocrinólogos/tendencias , Invenciones/tendencias , Pautas de la Práctica en Medicina/tendencias , Diabetes Mellitus/sangre , Diabetes Mellitus/epidemiología , Diabetes Mellitus/mortalidad , Diabetes Mellitus Tipo 1/sangre , Diabetes Mellitus Tipo 1/complicaciones , Diabetes Mellitus Tipo 1/terapia , Diabetes Mellitus Tipo 2/epidemiología , Diabetes Mellitus Tipo 2/prevención & control , Oído , Endocrinólogos/historia , Trastornos de Alimentación y de la Ingestión de Alimentos/complicaciones , Trastornos de Alimentación y de la Ingestión de Alimentos/epidemiología , Trastornos de Alimentación y de la Ingestión de Alimentos/terapia , Glucosa/análisis , Historia del Siglo XXI , Humanos , Invenciones/historia , Nitrilos/uso terapéutico , Pautas de la Práctica en Medicina/historia , Medicina de Precisión/historia , Medicina de Precisión/métodos , Medicina de Precisión/tendencias , Medicina Preventiva/tendencias , Pirazoles/uso terapéutico , Pirimidinas/uso terapéutico , Inducción de Remisión/métodos , Lágrimas/químicaRESUMEN
First detected in Wuhan, China, the novel 2019 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped RNA beta-coronavirus responsible for an unprecedented, worldwide pandemic caused by COVID-19. Optimal management of immunosuppression in inflammatory bowel disease (IBD) patients with COVID-19 infection currently is based on expert opinion, given the novelty of the infection and the corresponding lack of high-level evidence in patients with immune-mediated conditions. There are limited data regarding IBD patients with COVID-19 and no data regarding early pregnancy in the era of COVID-19. This article describes a patient with acute severe ulcerative colitis (UC) during her first trimester of pregnancy who also has COVID-19. The case presentation is followed by a review of the literature to date on COVID-19 in regard to inflammatory bowel disease and pregnancy, respectively.